| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-09 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-08 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-07 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.24 | 9e-07 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.24 | 5e-06 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.16 | 9e-06 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 4e-05 |